{
    "organizations": [],
    "uuid": "a095648133a99921c93fc1ea16e354af88b3c004",
    "author": "",
    "url": "https://www.reuters.com/article/brief-ema-validates-bristol-myers-type-i/brief-ema-validates-bristol-myers-type-ii-variation-application-for-opdivo-plus-yervoy-combination-for-treatment-of-first-line-metastatic-non-small-cell-lung-cancer-idUSFWN1SA0TR",
    "ord_in_thread": 0,
    "title": "BRIEF-EMA Validates Bristol-Myers' Type II Variation Application For Opdivo Plus Yervoy Combination For Treatment Of First-Line Metastatic Non-Small Cell Lung Cancer",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Market News May 3, 2018 / 12:42 PM / in 11 minutes BRIEF-EMA Validates Bristol-Myers' Type II Variation Application For Opdivo Plus Yervoy Combination For Treatment Of First-Line Metastatic Non-Small Cell Lung Cancer Reuters Staff 1 Min Read\nMay 3 (Reuters) - Bristol-Myers Squibb Co:\n* EUROPEAN MEDICINES AGENCY VALIDATES BRISTOL-MYERS SQUIBBâ€™S TYPE II VARIATION APPLICATION FOR OPDIVO PLUS YERVOY COMBINATION FOR TREATMENT OF FIRST-LINE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)\n* BRISTOL-MYERS SQUIBB CO - APPLICATION IS BASED ON DATA FROM PART 1 OF CHECKMATE -227, A GLOBAL PHASE 3 STUDY Source text for Eikon: Further company coverage:",
    "published": "2018-05-03T15:41:00.000+03:00",
    "crawled": "2018-05-03T16:00:28.042+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "market",
        "news",
        "may",
        "pm",
        "minute",
        "validates",
        "type",
        "ii",
        "variation",
        "application",
        "opdivo",
        "plus",
        "yervoy",
        "combination",
        "treatment",
        "metastatic",
        "cell",
        "lung",
        "cancer",
        "reuters",
        "staff",
        "min",
        "read",
        "may",
        "reuters",
        "squibb",
        "co",
        "european",
        "medicine",
        "agency",
        "validates",
        "squibb",
        "type",
        "ii",
        "variation",
        "application",
        "opdivo",
        "plus",
        "yervoy",
        "combination",
        "treatment",
        "metastatic",
        "cell",
        "lung",
        "cancer",
        "nsclc",
        "squibb",
        "co",
        "application",
        "based",
        "data",
        "part",
        "checkmate",
        "global",
        "phase",
        "study",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}